Drug Profile
Anti-CD19-CD137 chimeric antigen receptor T cell therapy - Sinobioway Cell Therapy
Alternative Names: CAR-CD19-modified T cells; CD19-CD137-ζ CAR-T cell; CD19-targeted CAR-T cells; Sino19 cellLatest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Sinobioway Cell Therapy
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diffuse large B cell lymphoma
- Phase I/II Leukaemia
- No development reported Lymphoma
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for clinical-Phase-Unknown development in Lymphoma(Recurrent) in China (Parenteral, Injection)
- 16 Mar 2021 Anti-CD19-CD137 chimeric antigen receptor T cell therapy is still in phase I/II trial for Leukaemia in China (Parenteral) (NCT02735291)
- 01 Dec 2018 Efficay and adverse events data from a phase I/II trial in Leukaemia presented at the 60th Annual Meeting and Exposition of the American Society of Hematology (ASH-2018)